This Act may be cited as the Lung Cancer Medicare Access to Precise Testing Act.

(a) Coverage Section 1861 of the Social Security Act (42 U.S.C. 1395xU.S. Code — Title 42, Section 1395xView official source on GovInfo) is amended— (1) in subsection (s)(2)— (A) in subparagraph (JJ), by adding and at the end; and (B) by adding at the end the following new subparagraph: (KK) lung cancer biomarker testing (as defined in subsection (nnn));; and (2) by adding at the end the following new subsection: (nnn) Lung cancer biomarker testing The term lung cancer biomarker testing means a test furnished on or after January 1, 2027, to an individual diagnosed with lung cancer for the identification of 1 or more specific biomarkers (such as genes, proteins, or other molecules) based on the analysis of such individual’s tissue, blood, or bodily fluids.. (b) Payment Section 1833(a)(1) of the Social Security Act (42 U.S.C. 1395y(a)(1)U.S. Code — Title 42, Section 1395y(a)(1)View official source on GovInfo) is amended— (1) by striking and (HH) and inserting (HH); and (2) by inserting, and (II) with respect to lung cancer biomarker testing (as defined in section 1861(nnn)), the amount paid shall be 100 percent of the reasonable charges for such testing before the semicolon at the end.